Target intelligence / Profile preview

Ribosomal protein L30 pseudogene 13 (RPL30P13)

Target: RPL30P13
Molecular classification: Other (specifically: Pseudogene, processed pseudogene; not a receptor, enzyme, transporter, transcription factor, or structural protein)

Overview

Ribosomal protein L30 pseudogene 13 (RPL30P13) is a noncoding, processed pseudogene derived from the ribosomal protein L30 gene family. Pseudogenes like RPL30P13 originate from once-functional genes that have acquired disabling mutations such as frameshifts, premature stop codons, or regulatory region mutations, rendering them incapable of producing a functional protein. RPL30P13 is one of numerous ribosomal protein pseudogenes scattered throughout the human genome and has no known biological, disease, or therapeutic relevance. For the functional gene, see Ribosomal protein L30 (RPL30), which encodes a component of the 60S ribosomal subunit involved in protein synthesis. RPL30P13 does not encode this protein and should not be confused with the functional RPL30 gene.

Other names: RPL30_7_1228RPL30P13

Mechanism of action

None. No drugs target this non-functional sequence, so there are no mechanisms of action

Biological functions

None known. As a pseudogene, RPL30P13 does not encode a functional product and has no confirmed biological function

Disease associations

None. RPL30P13 is not implicated in any disease as a causative or modulating factor. It is not associated with any known pathology

Safety considerations

None. No safety concerns are associated because it is not a functional protein nor a drug target

Interacting drugs

None. There are no drugs known or predicted to interact with this pseudogene

Biomarkers

None. RPL30P13 is not used as a biomarker for disease, patient selection, or therapeutic monitoring

Beyond the preview

Go deeper on Ribosomal protein L30 pseudogene 13 (RPL30P13).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ribosomal protein L30 pseudogene 13 (RPL30P13).

Explore the full profile